The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
Miso Robotics CEO Rich Hull discusses Flippy Fry Station, the future of AI-powered restaurant automation and how acquiring Zume's IP could reshape food robotics
After two years of AI-fueled spending, Wall Street is asking what's next. Gil Luria breaks down monetization, valuations, winners, losers, and AI's future.
FIFA’s soccer World Cup promises to deliver $11.1 billion in spending and $30.5 billion economic impact for the U.S., but how much is it really helping?
Bill Adams, Chief U.S. Economist at Fifth Third Bank, breaks down the Fed's latest decision, inflation risks, and what Kevin Warsh's debut means for markets.
